FK866, an FDA-approved iNAMPT inhibitor, has been shown to have antitumor properties through repression of cancer cell growth, dephosphorylation of the Erk and Akt pathways, and apoptotic induction, which could play an important role in cancers that are dependent on these pathways. The gene discussed is AKT1; the disease is cancer.